Somatropin Injection IP, Strength: 5 mg, Brand: Headon

Somatropin Injection IP 5 mg is a recombinant human growth hormone (rhGH) that is structurally identical to natural pituitary-derived growth hormone. It is produced using recombinant DNA technology in Escherichia coli or mammalian cells.

Somatropin is used to promote growth in children and maintain normal body composition in adults with growth hormone deficiency (GHD) and other related conditions.

• Children with:

  • Growth Hormone Deficiency (GHD)

  • Turner syndrome

  • Chronic renal insufficiency

  • Short stature homeobox-containing gene (SHOX) deficiency

  • Idiopathic short stature (ISS)

  • Small for gestational age (SGA) with failure to catch up

• Adults with:

  • Adult-onset or childhood-onset GHD

  • HIV-associated wasting or cachexia

  • Short bowel syndrome (as adjunct to specialized nutrition)

• Injection – Lyophilized powder for reconstitution

• Strength: 5 mg per vial

• To be reconstituted with 1–2 ml of sterile water for injection

Route of Administration:

• Subcutaneous (SC) injection (preferred)

• May also be administered intramuscularly in some cases

• Somatropin (rDNA origin) – 5 mg

• Excipients: Mannitol, glycine, phosphate buffer, sodium chloride (may vary by manufacturer)

• Diluent: Supplied separately as sterile water for injection

• 0.025–0.035 mg/kg/day SC

• Frequency: Once daily, usually in the evening

• Start with 0.2 mg/day; titrate based on IGF-1 levels and clinical response

• Max: Up to 1.0 mg/day

Note: Dosage should be individualized based on age, body weight, IGF-1 levels, and clinical response.

• Before reconstitution: Store at +2°C to +8°C (Refrigerated)

• After reconstitution: Use within 14 days (refrigerated); do not freeze

• Protect from light

• Single-use vial with 5 mg lyophilized somatropin

• Comes with or without sterile water for injection

• Supplied with leaflet and instructions for use

• Acute critical illness (e.g., post-surgery, trauma, or respiratory failure)

• Active malignancy

• Proliferative or severe non-proliferative diabetic retinopathy

• Known hypersensitivity to somatropin or excipients

• Monitor glucose levels – may induce insulin resistance or hyperglycemia

• Use with caution in patients with intracranial hypertension or scoliosis

• Monitor IGF-1 levels during treatment

• Evaluate for signs of tumor recurrence in patients with prior neoplasia.